BioAlliance Pharma SA has signed an collaboration agreement with one of the world leading vaccine companies to develop a vaccine application of its Lauriad mucoadhesive technology. The terms of this agreement are not disclosed at this time.

This research programme aims at establishing the feasibility of using Lauriad technology for vaccination, leading to an efficient needle-free administration based on the application to the gum of this mucoadhesive tablet containing a vaccine antigen. Moreover, this would also avoid the constraints related to manufacturing sterile injectable forms. This project is carried out within the FluriadTM consortium set in March 2011, co-labeled by both

“Clusters of excellence” Medicen Paris Region and Atlanpôle Biotherapies and financed up to €2 million by the “Fond Unique Interministériel” (a French programme supporting collaborative research projects).

“This collaboration with one of the world leading vaccine companies shows the potential interest of our innovative Lauriad system for a needle-free vaccination. This is also a major step taken to increase the value of our proprietary Lauriad technology, already validated through three major products of our portfolio: Loramyc and Sitavig, already registered, and Validive, in phase II clinical development,” stated Judith Greciet, CEO of BioAlliance Pharma. “A first successful feasibility would open the way to promising new opportunities in vaccine field with significant market potential worldwide.”

BioAlliance Pharma conceives and develops innovative products, for specialty markets especially in the hospital setting and for orphan or rare diseases.